Agency Information Collection Activities: Proposed Collection: Comment Request, 15111-15112 [2012-6135]
Download as PDF
<![CDATA[
srobinson on DSK4SPTVN1PROD with NOTICES
Federal Register / Vol. 77, No. 50 / Wednesday, March 14, 2012 / Notices
comments received will be posted
without change, including any personal
information provided. It is only
necessary to send one set of comments.
Identify comments with the docket
number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Comments received on or before April
26, 2012, will be provided to the
committee before the meeting.
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(rm. 1503), Silver Spring, MD 20993–
0002. Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
Contact Person: Yvette Waples, Center
for Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, FAX: 301–847–8533, email:
AVAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
A notice in the Federal Register about
last minute modifications that impact a
previously announced advisory
committee meeting cannot always be
published quickly enough to provide
timely notice. Therefore, you should
always check the Agency’s Web site and
call the appropriate advisory committee
hot line/phone line to learn about
possible modifications before coming to
the meeting.
Agenda: The committee will discuss
an efficacy supplement for new drug
application (NDA) 21–572, TRUVADA
(emtricitabine/tenofovir disoproxil
fumarate) Tablet, submitted by Gilead
Sciences, Inc. The supplemental
application proposes an indication for
Pre-Exposure Prophylaxis (PrEP) to
reduce the risk of sexually acquired
HIV–1 infection.
FDA intends to make background
materials available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
VerDate Mar<15>2010
17:29 Mar 13, 2012
Jkt 226001
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. All electronic and
written submissions submitted to the
Docket (see the ADDRESSES section of
this document) on or before April 26,
2012, will be provided to the committee.
Oral presentations from the public will
be scheduled between approximately 2
p.m. and 3 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before April 18,
2012. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by April 19, 2012.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Yvette
Waples at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
PO 00000
Frm 00090
Fmt 4703
Sfmt 4703
15111
Dated: March 8, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2012–6115 Filed 3–13–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection:
Comment Request
In compliance with the requirement
for opportunity for public comment on
proposed data collection projects
(section 3506(c)(2)(A) of Title 44, United
States Code, as amended by the
Paperwork Reduction Act of 1995, Pub.
L. 104–13), the Health Resources and
Services Administration (HRSA)
publishes periodic summaries of
proposed projects being developed for
submission to the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and draft instruments, email
paperwork@hrsa.gov or call the HRSA
Reports Clearance Officer at (301) 443–
1984.
Comments are invited on: (a) The
proposed collection of information for
the proper performance of the functions
of the agency; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology.
Proposed Project: Voluntary Partner
Surveys To Implement Executive Order
12862 in the Health Resources and
Services Administration—(OMB No.
0915–0212)—[Revision]
In response to Executive Order 12862,
the Health Resources and Services
Administration (HRSA) is proposing to
conduct voluntary customer surveys of
its partners to assess strengths and
weaknesses in program services and
processes. HRSA partners are typically
State or local governments, health care
facilities, health care consortia, health
care providers, and researchers. HRSA
is requesting a generic approval from
OMB to conduct the partner surveys.
E:\FR\FM\14MRN1.SGM
14MRN1
15112
Federal Register / Vol. 77, No. 50 / Wednesday, March 14, 2012 / Notices
Partner surveys to be conducted by
HRSA might include, for example, mail
or telephone surveys of grantees to
determine satisfaction with grant
processes or technical assistance
provided by a contractor, or in-class
evaluation forms completed by
providers who receive training from
HRSA grantees, to measure satisfaction
with the training experience. Results of
these surveys will be used to plan and
redirect resources and efforts as needed
to improve services and processes.
Focus groups may also be used to gain
partner input into the design of mail
and telephone surveys. Focus groups,
in-class evaluation forms, mail surveys,
and telephone surveys are expected to
be the preferred data collection
methods.
Responses
per
respondent
Number of
respondents
Instrument
A generic approval will permit HRSA
to conduct a limited number of partner
surveys without a full-scale OMB
review of each survey. If generic
approval is granted, information on each
individual partner survey will not be
published in the Federal Register.
The annual estimate of burden is as
follows:
Total
responses
Hours per
response
Total burden
hours
In-class evaluations .........................................................
Mail/Telephone surveys ...................................................
Focus groups ...................................................................
40,000
12,000
250
1
1
1
40,000
12,000
250
.05
.25
1.5
2,000
3,000
375
Total ..........................................................................
52,250
........................
........................
........................
5,375
Email comments to
paperwork@hrsa.gov or mail the HRSA
Reports Clearance Officer, Room 10–29,
Parklawn Building, 5600 Fishers Lane,
Rockville, MD 20857. Written comments
should be received within 60 days of
this notice.
Dated: March 7, 2012.
Reva Harris,
Acting Director, Division of Policy and
Information Coordination.
[FR Doc. 2012–6135 Filed 3–13–12; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
srobinson on DSK4SPTVN1PROD with NOTICES
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Agenda: To review and evaluate grant
applications.
Place: The St. Regis Washington, DC, 923
16th Street NW., Washington, DC 20006.
Contact Person: Phillip F. Wiethorn,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Blvd., Suite 3208, MSC 9529,
Bethesda, MD 20892, 301–496–5388,
wiethorp@ninds.nih.gov.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Udall Center Review.
Date: April 18–19, 2012.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco Baltimore, 2 North
Charles Street, Baltimore, MD 21201.
Contact Person: Birgit Neuhuber, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Blvd., Suite 3208, MSC 9529,
Bethesda, MD 20892,
neuhuber@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: March 8, 2012.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2012–6160 Filed 3–13–12; 8:45 am]
BILLING CODE 4140–01–P
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Neurosurgeon Scientific
Training.
Date: March 30, 2012.
Time: 8 a.m. to 5 p.m.
VerDate Mar<15>2010
17:29 Mar 13, 2012
Jkt 226001
PO 00000
Frm 00091
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel Loan Repayment Program
Review.
Date: April 30, 2012.
Time: 9 a.m. to 5 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: JoAnn McConnell, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
NINDS/NIH/DHHS/Neuroscience Center,
6001 Executive Blvd., Suite 3208, MSC 9529,
Bethesda, MD 20892, 301–496–5324,
mcconnej@ninds.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
E:\FR\FM\14MRN1.SGM
14MRN1
]]>Agencies
[Federal Register Volume 77, Number 50 (Wednesday, March 14, 2012)]
[Notices]
[Pages 15111-15112]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-6135]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Proposed Collection:
Comment Request
In compliance with the requirement for opportunity for public
comment on proposed data collection projects (section 3506(c)(2)(A) of
Title 44, United States Code, as amended by the Paperwork Reduction Act
of 1995, Pub. L. 104-13), the Health Resources and Services
Administration (HRSA) publishes periodic summaries of proposed projects
being developed for submission to the Office of Management and Budget
(OMB) under the Paperwork Reduction Act of 1995. To request more
information on the proposed project or to obtain a copy of the data
collection plans and draft instruments, email paperwork@hrsa.gov or
call the HRSA Reports Clearance Officer at (301) 443-1984.
Comments are invited on: (a) The proposed collection of information
for the proper performance of the functions of the agency; (b) the
accuracy of the agency's estimate of the burden of the proposed
collection of information; (c) ways to enhance the quality, utility,
and clarity of the information to be collected; and (d) ways to
minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology.
Proposed Project: Voluntary Partner Surveys To Implement Executive
Order 12862 in the Health Resources and Services Administration--(OMB
No. 0915-0212)--[Revision]
In response to Executive Order 12862, the Health Resources and
Services Administration (HRSA) is proposing to conduct voluntary
customer surveys of its partners to assess strengths and weaknesses in
program services and processes. HRSA partners are typically State or
local governments, health care facilities, health care consortia,
health care providers, and researchers. HRSA is requesting a generic
approval from OMB to conduct the partner surveys.
[[Page 15112]]
Partner surveys to be conducted by HRSA might include, for example,
mail or telephone surveys of grantees to determine satisfaction with
grant processes or technical assistance provided by a contractor, or
in-class evaluation forms completed by providers who receive training
from HRSA grantees, to measure satisfaction with the training
experience. Results of these surveys will be used to plan and redirect
resources and efforts as needed to improve services and processes.
Focus groups may also be used to gain partner input into the design of
mail and telephone surveys. Focus groups, in-class evaluation forms,
mail surveys, and telephone surveys are expected to be the preferred
data collection methods.
A generic approval will permit HRSA to conduct a limited number of
partner surveys without a full-scale OMB review of each survey. If
generic approval is granted, information on each individual partner
survey will not be published in the Federal Register.
The annual estimate of burden is as follows:
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total Hours per Total burden
Instrument respondents respondent responses response hours
----------------------------------------------------------------------------------------------------------------
In-class evaluations............ 40,000 1 40,000 .05 2,000
Mail/Telephone surveys.......... 12,000 1 12,000 .25 3,000
Focus groups.................... 250 1 250 1.5 375
-------------------------------------------------------------------------------
Total....................... 52,250 .............. .............. .............. 5,375
----------------------------------------------------------------------------------------------------------------
Email comments to paperwork@hrsa.gov or mail the HRSA Reports
Clearance Officer, Room 10-29, Parklawn Building, 5600 Fishers Lane,
Rockville, MD 20857. Written comments should be received within 60 days
of this notice.
Dated: March 7, 2012.
Reva Harris,
Acting Director, Division of Policy and Information Coordination.
[FR Doc. 2012-6135 Filed 3-13-12; 8:45 am]
BILLING CODE 4165-15-P
